Business Wire

FLIR Receives Additional $26M Contract for U.S. Army’s Nuclear, Biological and Chemical Reconnaissance Vehicle Program

15.10.2020 17:02:00 EEST | Business Wire | Press release

Share

FLIR Systems, Inc. (NASDAQ: FLIR) announced it has been awarded a $26 million contract modification in support of the Nuclear, Biological and Chemical Reconnaissance Vehicle Sensor Suite Upgrade (NBCRV SSU) program for the U.S. Army. The Other Transaction Authority (OTA) agreement was awarded through the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) as a follow-on to a $48 million contract announced in April 2019.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201015005675/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

FLIR is lead integrator in modernizing the U.S. Army’s Nuclear, Biological and Chemical Reconnaissance Vehicle (NBCRV) system with improved and autonomous CBRN sensors. Earlier this year, soldiers at Fort Bliss, Texas employed a FLIR prototype in realistic battlefield scenarios to sense and rapidly avoid CBRN hazards. The new contract allows FLIR to continue developing the Sensor Suite and also will pair the NBCRV with a ground robotic vehicle to expand the system’s use with manned-unmanned teams. (Photo: Business Wire)

FLIR is the lead integrator in modernizing the Army’s NBCRV system with improved and autonomous CBRN sensors. Earlier this year, the company delivered initial prototypes of the NBCRV SSU system for a focused assessment at Fort Bliss, Texas. Soldiers employed the FLIR prototype in realistic battlefield scenarios to sense and rapidly avoid CBRN hazards. The new contract allows FLIR to continue developing the Sensor Suite and to deliver mature prototypes for government testing in 2021.

Among other third-party solutions, the NBCRV Sensor Suite will feature capabilities of the FLIR R80D SkyRaider™ drone integrated with a specialized version of the FLIR IBAC bio-detection sensor. This next phase also will pair the NBCRV with a ground robotic vehicle to expand the system’s use with manned-unmanned teams. A FLIR-developed command and control system will bring together all devices and platforms with sensor fusion and automation features that lessen the cognitive burden on users and improve decision-making.

“Our ability to build and integrate manned and unmanned sensing solutions across a wide threat space is where FLIR differentiates itself,” said Vice President and General Manager of the Unmanned Systems & Integrated Solutions business at FLIR, Roger Wells. “Incorporating UAV and UGV platforms into NBCRV aligns with our efforts to develop full sensing capabilities that can act as force multipliers and boost mission success for our troops.

“Whether through air- or ground-based detection systems, FLIR is uniquely positioned in the defense industry with deep expertise in both intelligent sensor and autonomous systems technology that keeps warfighters safe,” Wells added.

FLIR is supporting other efforts by JPEO-CBRND. In the past year, the company has won two contracts worth more than $55 million to field its FLIR Agentase™ C2 chemical warfare disclosure spray, formulated to detect nerve agents like VX and sarin as well as blister agents such as sulfur mustard.

Work on the NBCRV program has begun and is expected to continue through 2022 at FLIR facilities in West Lafayette, Indiana; Stillwater, Oklahoma; and Elkridge, Maryland. For more on FLIR System’s integrated solutions for government and defense, visit www.flir.com/integrated-solutions. For more on FLIR’s chemical, biological, radiological, nuclear, and explosive detection technologies, visit www.flir.com/threat-detection.

About FLIR Systems, Inc.

Founded in 1978, FLIR Systems is a world-leading industrial technology company focused on intelligent sensing solutions for defense and industrial applications. FLIR Systems’ vision is to be “The World’s Sixth Sense,” creating technologies to help professionals make more informed decisions that save lives and livelihoods. For more information, please visit www.flir.com and follow @flir.

Forward Looking Statements

The statements in this release by Roger Wells and the other statements in this release about the contract and order described above are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based on current expectations, estimates, and projections about FLIR's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including the following: the ability to manufacture and deliver the systems referenced in this release, changes in pricing of FLIR's products, changing demand for FLIR's products, product mix, the impact of competitive products and pricing, constraints on supplies of critical components, excess or shortage of production capacity, the ability of FLIR to manufacture and ship products in a timely manner, FLIR's continuing compliance with U.S. export control laws and regulations, and other risks discussed from time to time in FLIR's Securities and Exchange Commission filings and reports. In addition, such statements could be affected by general industry and market conditions and growth rates, and general domestic and international economic conditions. Such forward-looking statements speak only as of the date on which they are made and FLIR does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release, or for changes made to this document by wire services or Internet service providers.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
Joe Ailinger, Jr.
FLIR Systems
Phone: +1 781-801-6161
Email: joe.ailinger@flir.com

Investor Relations:
Lasse Glassen
Addo Investor Relations
Phone: 424-238-6249
Email: lglassen@addoir.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye